Standard enteral nutrition
Dietary Supplementstandard enteral nutrition
Other names: control group
NCT Number: NCT02569203
To determine whether high-protein (24% of total calorie from protein) enteral nutrition of immune modulating nutrients (eg, ω-3 fatty acids and antioxidants) enriched with β-glucan stimulates immune functions compared with standard enteral nutrition (control: 20% of total calorie from protein) or high-protein (24% of total calorie from protein) enteral nutrition of immune modulating nutrients without β-glucan in critically ill patients.
Looking for future studies?
Notify MeAll sexes
Interventional
Not applicable
To determine whether high-protein (24% of total calorie from protein) enteral nutrition of immune modulating nutrients (eg, ω-3 fatty acids and antioxidants) enriched with β-glucan stimulates immune functions compared with standard enteral nutrition (control: 20% of total calorie from protein) or high-protein (24% of total calorie from protein) enteral nutrition of immune modulating nutrients without β-glucan in critically ill patients. In a randomized double-blind placebo-controlled study, 30 patients consumed 1 of 3 enteral nutrition: control, enteral nutrition of immune modulating nutrients enriched with β-glucan (250mg/L) or enteral nutrition of immune modulating nutrients without β-glucan. Enteral nutrition was initiated within 24 hours of ICU admission and continued during the ICU stay for a 7 days.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
standard enteral nutrition
Other names: control group
high-protein enteral nutrition of immune modulating nutrients enriched with β-glucan
Other names: test group I
high-protein enteral nutrition of immune modulating nutrients without β-glucan
Other names: test group II
Time frame: at baseline and 7 days follow-up
NK cell activity (%)
Time frame: at baseline and 7 days follow-up
IL-12 (pg/mL)
Time frame: at baseline and 7 days follow-up
hs-CRP (mg/dL)
Looking for future studies?
Notify MeYonsei University
Other
Effects of Enteral Formula Including Immune-modulating Nutrients on Clinical Course and Immune Function in Critically Ill Patients
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07842562
Acute Kidney Injury, Critical Illness
Yenimahalle, Ankara, Turkey (Türkiye)
View Trial DetailsNCT06019078
Agnosia, Analgesia
Abbotsford British Columbia, British Columbia, Canada
View Trial DetailsNCT07831564
Critical Illness, Critically Ill
Budapest, Hungary
View Trial DetailsNCT07418242
Acute Kidney Injury, Cardiac Surgery Associated - Acute Kidney Injury
Shanghai, Shanghai Municipality, China
View Trial Details